WhiteRabbit aims to bring to the market an innovative software platform. The platform will allow to extract value from personal data, while keeping its subjects in the loop and also complying with upcoming regulations. In the last 20 years the use of personal data generated a big but not still well-regulated market; this has resulted in problems to companies and SMEs like the escalating complexity of data privacy management, the misuse of data and its social/legal consequences. The upcoming General Data Protection Regulation (GDPR) in Europe, with its stricter rules, will introduce even higher complexity and costs for the management of personal data. In an ideal comparison with a well-known and regulated sector, the new software platform introduced by WhiteRabbit will work as an automated “tax accountant” helping companies to effectively deal with the complexity of regulations related to “tax returns”. Based on the prototype developed by the University of Trento within the “Smart Society” FET project, the WhiteRabbit project will bring such prototype to a further step of development through a new partnership with META Group, a leading company in the field of exploitation of research results, start-up creation, and access to finance. WhiteRabbit will validate the business model and design a commercialisation roadmap for the new start-up that will be launched by the team who developed the software platform’s original prototype. The consortium will then test the product in a market environment and finally will foster growth opportunities by pitching it to investors and potential customers. WhiteRabbit will generate an impact in terms of an innovation introduced into the market (the platform), the improvement of entrepreneurial mind-set (researchers becoming entrepreneurs within the start-up), and the stimulation of growth and jobs (a new start-up will be created).

Social Challenge Innovation Platform, SCHIP, aims at creating an online ecosystem to match pressing social challenges with innovative solutions, by supporting the co-development and execution by social innovators and SMEs of sustainable and market-oriented innovations with clear social impact. The action will enable European stakeholders to clearly define pressing social challenges; to promote a broad participation of social innovators, entrepreneurs and SMEs; to facilitate the testing of concrete solutions to prioritised challenges and their international scaling. SCHIP will provide a complementary grant-making mechanism, focused on the translation of challenges into practical and marketable solutions. The action will test a novel approach in the selection of solutions that is demand driven and user-centred. It will promote the ignition of these solutions by facilitating access to mentors, first clients and investors, and by building on the proven experience of the consortium networks in scaling social innovation across Europe. To maximise value for money and impact, SCHIP will leverage the know-how and reach out of the 3 partners: META Group with its long experience in managing financial instruments and meeting entrepreneurial needs; Impact Hub, the leading global network of centres for social innovation and social entrepreneurship with 85 Hubs, over 13,000 members and a proven track-record in managing social innovation challenge prizes; and EBN (The European Business and Innovation Centre Network), with its over 240 members, reaching out to more than 18,700 SMEs, 8750 start-ups and 485 large companies - 12% of them involved in social innovation related projects.

FET2RIN aims at facilitating collaborations to set the ground for the take up of FET projects by overcoming obstacles related to market outreach and accessing business leaders including entrepreneurs, early stage investors and crowdfunding communities. FET2RIN will deliver adhoc capacity building and market acceptancy actions to FET project partners to allow them to focus on novel exploitation rutes and unconventional business models to better meet the need of future societal and commercial impact. Proposed actions will stimulate researchers, entrepreneurs, business leaders working together to mutually understand opportunities disclosed by FET and cross-fertilize. Mentors and unconventional stakeholders business leaders, crowdfunding platforms will be engaged to validate market assumptions and speed up take up. Parnters will provide methodological support and capacity building actions based on the new trend of the customer validation process. To maximize impact, leverage on social recognition, seed opportunities for improving innovation potential of FET FET2RIN will reach out with ad hoc actions its target groups (FET Projects, entrepreneurs, business leaders, bakers) and offer opportunities for the mutual engagement of these communities when looking for market validation and acceptancy for FET results. Business leaders entrepreneurs will act as mentors for FET projects during capacity building customers and end users will be actively contacted leaving the labs. Such interaction among different communities and typology of stakeholders (for profit and not for profit, conventional and unconventional, etc.) will promotes cross-fertilization, mutual understanding and open up opportunities for further cooperation and take up.

The aim of MagElastic is to turn into a “ready for market” technology an innovation based on magnetoelastic micromotors, which was recently developed by FET-OPEN consortium ABIOMATER. It was demonstrated that such micromotors can function as microfluidic pumps, valves and stirrers, to manipulate liquids at microscopic scale. These properties show high potential in point-of-care (POC) diagnostics, since they allow for minimal volume of sample extraction, instantaneous application, and no reliance on the medical expertise or laboratory tools. The main objective of MagElastic is to set up a start-up/spin-off company for commercialising a blood plasma separation component which will enable to produce a range of point-of-care devices for diagnosis of many known illnesses. With only a prick of blood such a component can help saving a significant amount of time and costs, which are currently being lost in the necessity of involving specialised equipment and staff support to extract blood plasma. Because of it’s time efficiency, in some cases (such as Sepsis described below), such devices will allow to save lives. MagElastic will bring the current technology from TRL5/6 to TRL7 by engaging with early adopters that will test the new device in operational environment. Moreover MagElastic will pave the way for the commercialisation of the new device by meeting with potential customers, clients and commercial partners and facilitating access to potential investors. During the project, the University of Exeter and Platform Kinetics, owners of the results of the undergoing FET-OPEN project, will be supported by META Group, an experienced partner in exploitation of research results and access to investors.